Patient Death in Phase 2b Prostate Cancer Trial Unrelated to Topsalysin, Sophiris Says
News
Topsalysin (PRX302), an investigative agent for localized prostate cancer, is unlikely to have caused the death of a patient in a Phase 2b trial testing the medicine, Sophiris Bio announced. A review of clinical ... Read more